好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

WMH Progression but not Regression is Associated with a Higher CSF tau/Aß and Temporal Amyloid Concentration in The Amyloid PET Scan
Aging, Dementia, and Behavioral Neurology
P6 - Poster Session 6 (11:30 AM-1:00 PM)
9-008

Several studies report a strong association between Alzheimer’s Disease (AD) and cerebral WMH on MRI. These WMHs can grow in volume, regress or remain stable over time. We hypothesize that WMH progression is associated with higher levels of CSF tau/Amyloid beta (Aβ) and amyloid deposition quantified using amyloid (Florbetapir(18F); 18F-AV-45) positron emission tomography (PET).

To examine the differences between the white matter hyperintensities (WMH) progression versus the WMH regression groups in terms of cerebrospinal fluid amyloid beta level and amyloid deposition in the brain.

The sample consisted of 377 the Alzheimer’s Disease Neuroimaging Initiative 2 (ADNI2) participants who were evaluated with WMH quantification, cerebrospinal fluid levels of tau/Aβ and both total and regional amyloid deposition using an amyloid PET scan. All measures were collected at baseline with WMH additionally assessed 2 years later. Participants were categorized into three groups based on WMH change (Δ): Regression, Stable, and Progression.

Controlling for age and sex, there were no significant differences between those with WMH regression vs. progression in CSF tau/Aβ (p = 0.219), whole brain amyloid concentration (p = 0.169), or region-wise amyloid concentration (frontal, p = 0.177); cingulate, p = 0.153; parietal, p = 0.218; temporal, p = 0.164). Within-groups, change in WMH was positively correlated with tau/Aβ in the progression, but not regression group (p = 0.036 and p = 0.747, respectively). Amyloid PET scans showed that the change in WMH was not positively correlated with whole brain amyloid concentrations (p = 0.136), but there was a positive trend in the temporal region (p = 0.067) in the progression group. There were no significant differences in the regression group.

There were no significant differences in the regression group.WMH progression is associated with higher tau/Aβ and possibly temporal amyloid concentration based on amyloid PET scans. These results suggest that use of three WMH categories may help predict patient prognosis.

Authors/Disclosures
Omar M. Al-Janabi, MD, PhD, MSc
PRESENTER
Dr. Al-Janabi has nothing to disclose.
No disclosure on file
Chintan K. Rupareliya, MD (Ochsner Health Center) Dr. Rupareliya has nothing to disclose.
Larry B. Goldstein, MD, FAHA, FAAN (University of Kentucky) The institution of Dr. Goldstein has received research support from NIH. The institution of Dr. Goldstein has received research support from NIH. The institution of Dr. Goldstein has received research support from NIH. The institution of Dr. Goldstein has received research support from NIH. The institution of Dr. Goldstein has received research support from NIH. The institution of Dr. Goldstein has received research support from Janssen. Dr. Goldstein has received publishing royalties from a publication relating to health care.
Richard R. Murphy, MBChB, FAAN (Federal Aviation Administration) Dr. Murphy has nothing to disclose.
Charles D. Smith, MD, FAAN (Univ of Kentucky Med Ctr) No disclosure on file
Donna M. Wilcock, PhD (Indiana University) Dr. Wilcock has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AC Immune. Dr. Wilcock has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alector. Dr. Wilcock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AvroBio. Dr. Wilcock has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Neuroscience.
Gregory A. Jicha, MD, PhD (University of Kentucky College of Medicine) Dr. Jicha has nothing to disclose.
Brian Gold No disclosure on file